Other ATX inhibitors such as IOA-289 and PF8380, or BMS-986020, a LPAR1 antagonist, were developed and showed promising results in preclinical and clinical trials in other conditions [117,118,119,120]; however, they have not yet been tested in BC. Here, LPAR1 is linked to breast cancer.